Introduction: Overweight is a well-established risk factor for hidradenitis suppurativa (HS). In this cross-sectional study, we compare HS patients with a high body mass index (BMI) with HS patients with a low BMI to investigate differences in disease characteristics. Materials and method: Patients were recruited from 17 dermatological centres from four continents. A total of 246 patients with a BMI below 25 were compared to 205 patients with a BMI of above 35. Results: Patients with a high BMI suffered more severe disease (Hurley, physician global assessment, number of areas affected and patient-reported severity (PRS), P < 0.001 for all). There was no difference in smoking (P = 0.783) nor in family history (P = 0.088). In both low and high BMI patients, early onset of HS was a predictor of positive family history (P < 0.001, for each). For low BMI patients, an increase in BMI significantly increased PRS (P < 0.001). For patients with a high BMI, number of pack-years significantly increased PRS (P = 0.001). Cluster analysis of eruption patterns was location specific for low BMI patients but severity specific for high BMI patients. Discussion: Patients with a low and high BMI could represent two clinically different subtypes. We suggest a non-linear relationship between BMI and impact of HS. As patients go from a low BMI patient to a high BMI patient (or from high to low), eruption patterns and risk factors may change.
|Original language||English (US)|
|Number of pages||6|
|Journal||Journal of the European Academy of Dermatology and Venereology|
|State||Published - Feb 2018|
Bibliographical noteFunding Information:
Gregor B.E. Jemec: Honoraria from AbbVie, Inflarx, Leo pharma, Pierre-Fabre and Novartis for participation on advisory boards. Grants from Abbvie, Novartis, Regeneron and Leo Pharma for participation as an investigator. Research grants from Abbvie, Leo Pharma and Novartis. Ditte Marie Saunte was paid as a consultant for advisory board meeting by AbbVie and received speakers’ honoraria and/or received grants from the following companies: Bayer, Abbvie, Desitin, Pfizer, Galderma, Astellas, Novartis and Leo Pharma. Christos C. Zouboulis: Relevant honoraria from AbbVie, Celgene, Inflarx, Novartis and UCB for participation on advisory boards, as a consultant, and speaker. His department received relevant grants from AbbVie, Biogen, Celgene and Novartis for participation as an investigator. Other authors stated no conflict of interest.
© 2017 European Academy of Dermatology and Venereology